HRP20171295T1 - Derivat 6-okso-1,6-dihidro-piridazina za upotrebu za liječenje hepatocelularnog karcinoma (hcc) - Google Patents
Derivat 6-okso-1,6-dihidro-piridazina za upotrebu za liječenje hepatocelularnog karcinoma (hcc) Download PDFInfo
- Publication number
- HRP20171295T1 HRP20171295T1 HRP20171295TT HRP20171295T HRP20171295T1 HR P20171295 T1 HRP20171295 T1 HR P20171295T1 HR P20171295T T HRP20171295T T HR P20171295TT HR P20171295 T HRP20171295 T HR P20171295T HR P20171295 T1 HRP20171295 T1 HR P20171295T1
- Authority
- HR
- Croatia
- Prior art keywords
- dihydro
- oxo
- hcc
- treatment
- hepatocellular carcinoma
- Prior art date
Links
- 206010073071 hepatocellular carcinoma Diseases 0.000 title claims 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title claims 5
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title 1
- AHYMHWXQRWRBKT-UHFFFAOYSA-N tepotinib Chemical compound C1CN(C)CCC1COC1=CN=C(C=2C=C(CN3C(C=CC(=N3)C=3C=C(C=CC=3)C#N)=O)C=CC=2)N=C1 AHYMHWXQRWRBKT-UHFFFAOYSA-N 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 2
- KZVOMLRKFJUTLK-UHFFFAOYSA-N 3-[1-[[3-[5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl]phenyl]methyl]-6-oxopyridazin-3-yl]benzonitrile;hydrate;hydrochloride Chemical compound O.Cl.C1CN(C)CCC1COC1=CN=C(C=2C=C(CN3C(C=CC(=N3)C=3C=C(C=CC=3)C#N)=O)C=CC=2)N=C1 KZVOMLRKFJUTLK-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (4)
1. 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoksi)-pirimidin-2-il]-benzil}-6-okso-1,6-dihidro-piridazin-3-il)-benzonitril ili njegova farmaceutski prihvatljiva sol i/ili solvat naznačen time da je za upotrebu za liječenje hepatocelularnog karcinoma (HCC).
2. 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoksi)-pirimidin-2-il]-benzil}-6-okso-1,6-dihidro-piridazin-3-il)-benzonitril hidroklorid hidrat naznačen time da je za upotrebu za liječenje hepatocelularnog karcinoma (HCC).
3. 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoksi)-pirimidin-2-il]-benzil}-6-okso-1,6-dihidro-piridazin-3-il)-benzonitril prema zahtjevu 1 ili 2, naznačen time da se spoj daje pacijentu u količini od 100 mg do 800 mg dnevno.
4. 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoksi)-pirimidin-2-il]-benzil}-6-okso-1,6-dihidro-piridazin-3-il)-benzonitril prema zahtjevu 1, 2 ili 3, naznačen time da se spoj daje oralno.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12007494 | 2012-11-02 | ||
| PCT/EP2013/002998 WO2014067610A1 (en) | 2012-11-02 | 2013-10-04 | A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc) |
| EP13776720.8A EP2914264B1 (en) | 2012-11-02 | 2013-10-04 | A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171295T1 true HRP20171295T1 (hr) | 2017-10-20 |
Family
ID=47143496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171295TT HRP20171295T1 (hr) | 2012-11-02 | 2017-08-28 | Derivat 6-okso-1,6-dihidro-piridazina za upotrebu za liječenje hepatocelularnog karcinoma (hcc) |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20150283137A1 (hr) |
| EP (1) | EP2914264B1 (hr) |
| JP (1) | JP6255028B2 (hr) |
| KR (1) | KR102131588B1 (hr) |
| CN (1) | CN104768553A (hr) |
| AR (1) | AR093318A1 (hr) |
| AU (1) | AU2013339823B2 (hr) |
| BR (1) | BR112015008279A2 (hr) |
| CA (1) | CA2890273C (hr) |
| DK (1) | DK2914264T3 (hr) |
| ES (1) | ES2646913T3 (hr) |
| HK (1) | HK1211869A1 (hr) |
| HR (1) | HRP20171295T1 (hr) |
| HU (1) | HUE035483T2 (hr) |
| IL (1) | IL238536B (hr) |
| LT (1) | LT2914264T (hr) |
| MX (1) | MX354518B (hr) |
| NO (1) | NO2914264T3 (hr) |
| PL (1) | PL2914264T3 (hr) |
| PT (1) | PT2914264T (hr) |
| RS (1) | RS56485B1 (hr) |
| RU (1) | RU2650679C2 (hr) |
| SG (1) | SG11201503214YA (hr) |
| SI (1) | SI2914264T1 (hr) |
| WO (1) | WO2014067610A1 (hr) |
| ZA (1) | ZA201503924B (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114698541A (zh) | 2013-08-14 | 2022-07-05 | 有限会社日本通商 | 水栽培系统和设置有水栽培系统的植物工厂 |
| JP2022540170A (ja) * | 2019-07-10 | 2022-09-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬調製物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005057924A1 (de) * | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102007032507A1 (de) * | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| KR101829595B1 (ko) * | 2009-01-08 | 2018-02-14 | 메르크 파텐트 게엠베하 | 3-（1-｛3-［5-（1-메틸-피페리딘-4일메톡시）-피리미딘-2-일］-벤질｝-6-옥소-1,6-디히드로-피리다진-3-일）-벤조니트릴 히드로클로라이드 염의 신규한 다형체 및 이의 제조 방법 |
-
2013
- 2013-10-04 PT PT137767208T patent/PT2914264T/pt unknown
- 2013-10-04 JP JP2015541023A patent/JP6255028B2/ja active Active
- 2013-10-04 HU HUE13776720A patent/HUE035483T2/hu unknown
- 2013-10-04 MX MX2015005265A patent/MX354518B/es active IP Right Grant
- 2013-10-04 KR KR1020157014482A patent/KR102131588B1/ko active IP Right Grant
- 2013-10-04 US US14/440,181 patent/US20150283137A1/en not_active Abandoned
- 2013-10-04 AU AU2013339823A patent/AU2013339823B2/en active Active
- 2013-10-04 RU RU2015120692A patent/RU2650679C2/ru active
- 2013-10-04 LT LTEP13776720.8T patent/LT2914264T/lt unknown
- 2013-10-04 DK DK13776720.8T patent/DK2914264T3/en active
- 2013-10-04 SI SI201330832T patent/SI2914264T1/sl unknown
- 2013-10-04 CA CA2890273A patent/CA2890273C/en active Active
- 2013-10-04 EP EP13776720.8A patent/EP2914264B1/en active Active
- 2013-10-04 PL PL13776720T patent/PL2914264T3/pl unknown
- 2013-10-04 CN CN201380057293.0A patent/CN104768553A/zh active Pending
- 2013-10-04 ES ES13776720.8T patent/ES2646913T3/es active Active
- 2013-10-04 NO NO13776720A patent/NO2914264T3/no unknown
- 2013-10-04 SG SG11201503214YA patent/SG11201503214YA/en unknown
- 2013-10-04 RS RS20171129A patent/RS56485B1/sr unknown
- 2013-10-04 WO PCT/EP2013/002998 patent/WO2014067610A1/en active Application Filing
- 2013-10-04 BR BR112015008279A patent/BR112015008279A2/pt not_active Application Discontinuation
- 2013-11-01 AR ARP130103990A patent/AR093318A1/es not_active Application Discontinuation
-
2015
- 2015-04-30 IL IL238536A patent/IL238536B/en active IP Right Grant
- 2015-06-01 ZA ZA2015/03924A patent/ZA201503924B/en unknown
-
2016
- 2016-01-04 HK HK16100004.6A patent/HK1211869A1/xx unknown
-
2017
- 2017-08-28 HR HRP20171295TT patent/HRP20171295T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201503924B (en) | 2020-11-25 |
| KR102131588B1 (ko) | 2020-07-08 |
| LT2914264T (lt) | 2017-11-10 |
| AR093318A1 (es) | 2015-05-27 |
| KR20150079942A (ko) | 2015-07-08 |
| SI2914264T1 (sl) | 2017-12-29 |
| EP2914264A1 (en) | 2015-09-09 |
| CA2890273C (en) | 2021-10-26 |
| JP2015536957A (ja) | 2015-12-24 |
| PT2914264T (pt) | 2017-11-14 |
| NO2914264T3 (hr) | 2018-01-06 |
| PL2914264T3 (pl) | 2017-12-29 |
| CN104768553A (zh) | 2015-07-08 |
| CA2890273A1 (en) | 2014-05-08 |
| JP6255028B2 (ja) | 2017-12-27 |
| RU2015120692A (ru) | 2016-12-27 |
| BR112015008279A2 (pt) | 2017-07-04 |
| IL238536B (en) | 2019-01-31 |
| US20150283137A1 (en) | 2015-10-08 |
| MX2015005265A (es) | 2015-07-17 |
| SG11201503214YA (en) | 2015-05-28 |
| RS56485B1 (sr) | 2018-01-31 |
| EP2914264B1 (en) | 2017-08-09 |
| AU2013339823B2 (en) | 2018-01-04 |
| WO2014067610A1 (en) | 2014-05-08 |
| HK1211869A1 (en) | 2016-06-03 |
| IL238536A0 (en) | 2015-06-30 |
| DK2914264T3 (en) | 2017-09-11 |
| HUE035483T2 (hu) | 2018-05-02 |
| AU2013339823A1 (en) | 2015-06-18 |
| MX354518B (es) | 2018-03-08 |
| ES2646913T3 (es) | 2017-12-18 |
| RU2650679C2 (ru) | 2018-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201300309A (es) | Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2- pirimidinil]-amino]-n-[5-(4-metil -1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos | |
| HRP20182059T1 (hr) | Polimorfi i soli 6-(1h-indol-4-il)-4-(5-{[4-(1-metiletil)-1-piperazinil]metil}-1,3-oksazol-2-il)-1h-indazola kao inhibitori pi3k, namijenjeni upotrebi u liječenju, primjerice, dišnih poremećaja | |
| EA201100358A1 (ru) | Дабигатран для чрескожной хирургической катетеризации сердца | |
| MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
| NZ600310A (en) | 4-[2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine salts | |
| NZ720328A (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
| RS53807B1 (en) | N- (4 - ((3- (2-AMINO-4-Pyrimidinyl) -2-pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of cancer resistant ANTIMITOTIC AGENCIES | |
| JP2015537009A5 (hr) | ||
| PH12017502252A1 (en) | Stable pharmaceutical composition for oral administration | |
| HRP20171295T1 (hr) | Derivat 6-okso-1,6-dihidro-piridazina za upotrebu za liječenje hepatocelularnog karcinoma (hcc) | |
| AR093635A1 (es) | Inhibidores de la tirosina quinasa de bruton, metodo de tratamiento, compuesto, combinacion, formulacion | |
| SG11201604517WA (en) | Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof | |
| GT201400094A (es) | Formulación de liberación inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)-fenil]-benzamida | |
| BR112017010232A2 (pt) | Combinação de um derivado de 6-oxo-1,6-di-hidro- piridazina tendo atividade anticâncer com um derivado de quinazolina | |
| BR112017012136A2 (pt) | Combinação de um derivado de 6-oxo-1,6-di-hidro- piridazina tendo atividade anticâncer com um inibidor de egfr | |
| JP2015536957A5 (hr) | ||
| BR112015007870A2 (pt) | combinação de um derivado de 6-oxo-1,6-di-hidro-piridazina tendo atividade anticâncer com um inibidor de mek | |
| AU2014365665A1 (en) | Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions | |
| MX2015017058A (es) | Combinaciones farmaceuticas de un inhibidor de pi3k y un agente de desestabilizacion de microtubulos. | |
| RU2016132401A (ru) | Производное 6-оксо-1, 6-дигидро-пиридазина для применения для лечения почечно-клеточного рака (rcc) | |
| JP2013542262A5 (hr) | ||
| HRP20201574T1 (hr) | Supstituirani nikotinimidni inhibitori btk, njihova priprava i upotreba u liječenju raka, upale i autoimunih bolesti | |
| JP2014240383A5 (hr) | ||
| JP2014520147A5 (hr) | ||
| TN2013000440A1 (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids |